C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Eesults from the ASCENT trial

Cancer

Volumn 112, Issue 11, 2008, Pages 2377-2383

  Beer, Tomasz M ^a   Lalani, Alshad S ^b   Lee, Stella ^b   Mori, Motomi ^c   Eilers, Kristine M ^a   Curd, John G ^b   Henner, W David ^b   Ryan, Christopher W ^a   Venner, Peter ^d   Ruether, J Dean ^e   Chi, Kim N ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Novacea Inc   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

C reactive protein; Inflammation; Prognostic factors; Prostate cancer

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCITRIOL; CHEMOKINE; CYTOKINE; DEXAMETHASONE; DOCETAXEL; HEMOGLOBIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL STIMULATING AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HAZARD RATIO; HUMAN; IMMUNOASSAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK; TREATMENT RESPONSE; BLOOD; CANCER STAGING; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CALCITRIOL; CALCIUM CHANNEL AGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PLACEBOS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 52049085538     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23461     Document Type: Article

References (36)

1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
3. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972-3982.
4. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
7. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641-648.
8. Zeh HJ 3rd, Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother. 2005;28:1-9.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
10. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.
11. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985-1992.
12. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001;98: 14565-14570.
13. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224-1235.
14. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep. 2000;7:169-170.
15. Norrish AE, Jackson RT, McRae CU. Non-steroidal antiinflammatory drugs and prostate cancer progression. Int J Cancer. 1998;77:511-515.
16. Neugut AI, Rosenberg DJ, Ahsan H, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev. 1998; 7:869-873.
17. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250-255.
18. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25:669-674.
19. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17:3461-3467.
20. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344.
21. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994;69:911-913.
22. Legouffe E, Rodriguez C, Picot MC, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma. 1998;31:351-357.
23. Kodama J,Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;82:107-110.
24. Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354-356.
25. Huang A, Tsavellas G. Acute-phase protein, survival and tumour recurrence in patients with colorectal cancer Br J Surg. 2001;88:255-260.
26. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995;75:2077-2082.
27. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 1999;35:106-110.
28. Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995;85:765-771.
29. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127-129.
30. Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274-278.
31. Jaye DL,Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J. 1997;16:735-746; quiz 746-747.
32. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117:104-111.
33. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006;12:5578-5586.
34. George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005;11:1815-1820.
35. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993;91:1351-1357.
36. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.